Trial · NCT02666664
Outcomes30
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 30
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | Up to approximately 52 weeks | Safety Population: all randomized participants who received at least 1 dose of investigational medicinal product. Participants were included in the treatment group that they received, regardless of their randomized treatment. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With Adjudicated Major Adverse Cardiovascular Event | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Creatine Kinase Elevations | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Hepatic Disorders | Up to approximately 52 weeks | Safety Population. The percentage of unique participants is reported in the Overall hepatic disorder AESIs category; a participant could have been represented in more than one of the individual hepatic disorder AESIs. | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Hypoglycemia | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Metabolic Acidosis | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Muscular Disorder | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Neurocognitive Disorder | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: New Onset or Worsening Diabetes Mellitus | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With the Indicated Event of Special Interest: Renal Disorder | Up to approximately 52 weeks | Safety Population | percentage of participants | NUMBER |
| PRIMARY | Change From Baseline to Week 52 in Uric Acid (Urate) Level | Baseline and Week 52 | Safety Population. Only participants with available data were analyzed. | milligrams per deciliter (mg/dL) | MEAN |
| PRIMARY | Change From Baseline to Week 52 in Creatinine Level | Baseline and Week 52 | Safety Population. Only participants with available data were analyzed. | mg/dL | MEAN |
| PRIMARY | Change From Baseline to Week 52 in Hemoglobin Level | Baseline and Week 52 | Safety Population. Only participants with available data were analyzed. | grams per deciliter (g/dL) | MEAN |
| SECONDARY | Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C) | Baseline; Week 12 | Full Analysis Set: all randomized participants | percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Absolute Change From Baseline to Week 12 in LDL-C | Baseline; Week 12 | Full Analysis Set. Only participants with available data were analyzed. | mg/dL | MEAN |
| OTHER_PRE_SPECIFIED | Percent Change From Baseline to Week 24 in LDL-C | Baseline; Week 24 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| OTHER_PRE_SPECIFIED | Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) | Baseline; Week 12 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| OTHER_PRE_SPECIFIED | Percent Change From Baseline to Week 12 in Total Cholesterol (TC) | Baseline; Week 12 | Full Analysis Set | percent change | LEAST_SQUARES_MEAN |
| OTHER_PRE_SPECIFIED | Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB) | Baseline; Week 12 | Full Analysis Set. Only participants with available data were analyzed. | percent change | LEAST_SQUARES_MEAN |
| OTHER_PRE_SPECIFIED | Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP) | Baseline; Week 12 | Full Analysis Set. Only participants with available data were analyzed. | percent change | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02666664/outcomes